Onalespib

DRUG6 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Advanced Breast CarcinomaAdvanced Malignant Solid NeoplasmBRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Breast CarcinomaMetastatic High Grade Fallopian Tube Serous AdenocarcinomaMetastatic Malignant Solid NeoplasmMetastatic Melanoma

Phase 1

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

TerminatedNCT02097225

National Cancer Institute (NCI)BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Neoplasm +7

Start: 2014-05-29End: 2022-10-26Updated: 2024-10-16

Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin

CompletedNCT02381535

National Cancer Institute (NCI)Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 +9

Start: 2015-10-22End: 2020-04-24Updated: 2025-02-11

Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer

TerminatedNCT02474173

National Cancer Institute (NCI)Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Stage IIIA Breast Cancer AJCC v7 +5

Start: 2016-01-15End: 2022-10-26Updated: 2022-11-04

Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

CompletedNCT02503709

National Cancer Institute (NCI)Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Solid Neoplasm

Start: 2016-09-30End: 2020-10-09Updated: 2025-02-10

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

CompletedNCT02898207

National Cancer Institute (NCI)Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Primary Peritoneal Serous Adenocarcinoma +16

Start: 2017-05-19End: 2022-01-14Updated: 2023-04-26

Phase 2

Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL

TerminatedNCT02572453

National Cancer Institute (NCI)Recurrent Anaplastic Large Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma +5

Start: 2016-04-04End: 2021-03-18Updated: 2022-09-13

Related Papers

Abstract PS4-01-15: Acute and Early Circulating Tumor DNA Dynamics in Metastatic Triple-Negative Breast Cancer Targeted Therapy Phase Ib/II Clinical Trials

Clinical Cancer Research2026-02-17

Abstract 7632: Final survival outcomes and post-hoc tumor gene expression pathway analyses of complete responders from a phase Ib clinical trial of HSP90 inhibitor onalespib and paclitaxel in patients with advanced triple-negative breast cancer

Cancer Research2024-03-22

Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer.

2023-12-255 citations

Dose‐escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with <i>BRAF</i>‐mutant solid tumors

Cancer2023-04-119 citations

CTEP 9557: A dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF mutant solid tumors.

Journal of Clinical Oncology2020-05-204 citations

Phase I trial of the combination of the heat shock protein-90 inhibitor onalespib (AT13387) and the cyclin-dependent kinase inhibitor AT7519M in patients with advanced solid tumors.

Journal of Clinical Oncology2019-05-204 citations

Phase 1 study of onalespib, HSP90 inhibitor, and AT7519M, CDK9 inhibitor, in patients with advanced solid tumors.

Journal of Clinical Oncology2017-05-201 citations

Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173).

Journal of Clinical Oncology2017-05-20

Abstract CT033: Phase 1b study of heat shock protein 90 inhibitor onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173)

Cancer Research2016-07-15